View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
September 3, 2021

UK expands funding to trial Ibex’s AI-based prostate cancer diagnostic

The technology will be used to identify and grade cancer in prostate biopsies from samples of 600 men across 14 months.

The UK Government has announced funding for six new National Health Service (NHS) trusts in England that will take part in the clinical trial assessing Ibex Medical Analytics ’ artificial intelligence (AI) technology to quickly detect prostate cancer.

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

This is said to be the largest multi-site rollout of AI in the UK.

Approximately 100,000 men receive a prostate biopsy each year in the UK, and this number is estimated to increase two-fold over the next decade.

The new AI technology, named Galen Prostate, is designed to analyse biopsy images for the automatic and precise diagnosis of prostate cancer. It is intended to accelerate diagnoses and reduce diagnostic errors.

During the clinical trial, the AI analysis results will be compared with existing diagnosis approaches, where a pathologist accurately reviews biopsies.

Galen Prostate will be used to identify and grade cancer using prostate biopsies from samples of 600 men across 14 months.

UK Secretary of State for Health and Social Care Sajid Javid said: “AI has the potential to transform our health and care system and studies like this are vital in understanding the impact AI can make.

“Cancer diagnosis and treatment has remained a top priority throughout the pandemic and I am committed to busting the backlog in cancer care.

“The earlier cancer is detected the quicker it is treated, leading to better outcomes for patients, so this groundbreaking work has the potential to benefit thousands of people.”

The government is offering the funding as part of the £140m NHSX AI in Health and Care awards.

With the funding support to deploy and assess the AI diagnostic, broader use of the technology is expected across the health service to reduce diagnosis durations and free up clinician time.

Ibex Medical Analytics CEO and co-founder Joseph Mossel said: “The UK is clearly on track to become a world leader in implementing AI technologies in healthcare and we look forward to cooperating with our NHS partners and introducing our AI solution into multiple pathology labs in the UK.”

Related Companies

Free Report
img

What’s missing from your IPO industry assessment?

IPO activity all but stopped in 2020, as the investment community grew wary of the effects of COVID-19 on economies. No matter how deserving a business was of flotation, momentum was halted by concerns of when a ‘new normal’ of working patterns and trade would set in. Recently, sentiment has changed. Flotations picked up again during the second half of 2021, and now in 2022 the mood is decidedly optimistic. Business leaders have their eyes on fast rebounding economies, buoyant market indices and the opportunity once again to take their businesses public. As a result, global IPOs are expected to hit back this year. With GlobalData’s new whitepaper, ‘IPOs in Consumer and Retail: 5 must-include elements for your prospectus industry report’, you can explore exactly what is needed in the essential literature. GlobalData’s focus lies in the critical areas to get right:
  • Macroeconomic and demographic environment
  • Consumer context
  • Industry environment
  • Competitive environment
  • Route to market
Interested to learn more about what to include in your IPO Industry Assessment report? Download our free whitepaper.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network